Download - Glenmark
Download - Glenmark
Download - Glenmark
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Given below is the summary of financial assets as categorised in IAS 39:<br />
Particulars 31 March 2011<br />
Non-current assets<br />
Available - for - sale 2.68<br />
Held - to - maturity 278.58<br />
281.26<br />
Current assets<br />
Available - for - sale -<br />
Loans and receivables (including Cash and cash equivalents) 17,229.51<br />
NOTE AA - OTHER FINANCIAL LIABILITIES<br />
Trade and other payables principally comprise amounts outstanding for trade purchases and ongoing costs.<br />
The management consider that the carrying amount of trade payables approximates to their fair value.<br />
Given below is the summary of financial liabilities as categorised in IAS 39:<br />
Particulars 31 March 2011<br />
Non-current liabilities<br />
Borrowings:<br />
Financial liabilities at amortised cost 6,202.49<br />
Current liabilities<br />
Borrowings:<br />
Financial liabilities at amortised cost 14,913.96<br />
Trade and other payables:<br />
Financial liabilities at amortised cost 7,493.94<br />
NOTE BB - FAIR VALUE HIERARCHY<br />
The following table presents financial assets and liabilities measured at fair value in the statement of financial position in<br />
accordance with the fair value hierarchy. This hierarchy groups financial assets and liabilities into three levels based on the<br />
significance of inputs used in measuring the fair value of the financial assets and liabilities. The fair value hierarchy has<br />
the following levels:<br />
- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;<br />
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either<br />
directly (i.e. as prices) or indirectly (i.e. derived from prices); and<br />
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).<br />
The level within which the financial asset or liability is classified is determined based on the lowest level of significant input<br />
to the fair value measurement. The financial assets and liabilities measured at fair value in the Consolidated statement of<br />
financial position are grouped into the fair value hierarchy as follows:<br />
Particulars Level 1 Level 2 Level 3 Total<br />
Assets<br />
Available - for - sale financial assets – Investment<br />
in unlisted securities - - 2.64 2.64<br />
Liabilities - - - -<br />
Measurement of fair value<br />
The methods and valuation techniques used for the purpose of measuring fair value are unchanged from the previous year.<br />
Investments in unlisted securities<br />
The fair value of the investment cannot be determined as there are no quoted market prices at the reporting date for<br />
unlisted securities and hence they have been valued at cost. Such investments have been categorised in Level 3.<br />
NOTE CC - RISK MANAGEMENT OBJECTIVES AND POLICIES<br />
The Group is exposed to a variety of financial risks which results from the Group’s operating and investing activities. The<br />
Group’s risk management is co-ordinated by its parent company, in close co-operation with the board of directors and the<br />
core management team of the subsidiaries, and focuses on actively securing the Group’s short to medium term cash flows<br />
by minimising the exposure to financial markets.<br />
The Group does not actively engage in the trading of financial assets for speculative purposes nor does it write options.<br />
Financial assets that potentially subject the Group to concentrations of credit risk consist principally of cash equivalents,<br />
accounts receivables, other receivables, investment securities and deposits. By their nature, all such financial instruments<br />
involve risk including the credit risk of non-performance by counter parties.<br />
The Group’s cash equivalents and deposits are invested with banks.<br />
104 GLENMARK PHARMACEUTICALS LIMITED